このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

2026年9月16日 更新者:University of Arizona

GLP-1 Receptor Agonist Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. The goal of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and correlative analyses of combining GLP-1 RAs with standard chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.

調査の概要

詳細な説明

The United States is facing a growing epidemic of obesity and type 2 diabetes, with over 42% of adults now classified as obese and nearly 20% of children affected by obesity. This rise has been driven by a combination of poor dietary habits, sedentary lifestyles, and social and economic factors that limit access to healthy food and healthcare. Type 2 diabetes, closely linked to obesity, affects more than 37 million Americans, with an additional 96 million adults estimated to have prediabetes. These conditions not only contribute to significant personal health burdens but also cost the U.S. economy over $370 billion annually. Disparities are evident, with higher rates among Black, Hispanic, Native American, low-income, and rural populations, largely due to systemic barriers and social determinants of health. In response, public health initiatives have promoted better nutrition, physical activity, and early intervention programs. New medications, such as GLP-1 receptor agonists, offer promising tools for weight loss and diabetes management, though their accessibility remains limited by cost and insurance coverage.

Prescription data show GLP 1 RA use has exploded in recent years. For example, GLP 1 prescribing volume in the U.S. roughly tripled from early 2020 to late 2022, and annual spending jumped from $13.7 billion in 2018 to $71.7 billion by 2023 (a 62% increase in just 2022-23). Semaglutide products (Ozempic/WEGOVY) still account for the largest share of use, but Lilly's tirzepatide (Mounjaro/Zepbound) has gained market share rapidly. Uptake is broadening across age groups. Surveys indicate ~19% of adults ages 50-64 and 8% of those ≥65 have tried GLP 1 drugs (mainly for diabetes) and prescribing to adolescents with obesity surged ~300% in 2023 (albeit reaching only ~0.5% of obese youth). Looking ahead, analysts project continued robust growth. One forecast estimates U.S. GLP 1 weight loss drug sales rising from about $10 B in 2024 to ~$37 B by 2030 (≈19% CAGR). Globally, GLP 1 market revenue (diabetes + obesity) could approach $130 B by 2030, with the leading agents (semaglutide and tirzepatide lines) alone generating on the order of $100 B by decade's end. This outlook reflects expanding approved uses (e.g. heart disease, potential NASH indications) and large unmet need (only ~10-12% of U.S. adults have used GLP 1s despite over half of adults being overweight or obese). Taken together, the data indicate an unprecedented growth trajectory for GLP 1 RAs, with rapid year over year prescription gains and forecasts of very high revenues and market dominance through 2030.

Similarly, pancreatic cancer and hepatocellular carcinoma are also associated with modifiable risk factors including obesity, dietary factors, and diabetes. Consequently, there is a growing number of patients diagnosed with GI cancers who are also simultaneously being treated with GLP-1 RAs. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. This highlights an unmet need to investigate the safety of GLP-1 RA use during chemotherapy treatment for patients with metastatic colorectal cancer, pancreatic cancer, and hepatocellular carcinoma. Furthermore, emerging evidence supports investigation of GLP-1 RAs on metabolic modulation, insulin resistance reduction, and potential anti-inflammatory effects from GLP-1 RAs in oncology settings. Both cancer types may benefit from adjunctive metabolic therapy, particularly in patients at risk of sarcopenia, cachexia, or insulin resistance.

This trial aims to investigate the safety, tolerability, and efficacy of GLP-1 receptor agonist treatment in combination with standard of care (SOC) chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.

研究の種類

介入

入学 (推定)

30

段階

  • 初期フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Arizona
      • Tucson、Arizona、アメリカ、85724
        • 募集
        • University of Arizona Cancer Center
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Aaron J Scott, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Histological or cytological diagnosis of pancreatic adenocarcinoma or colorectal adenocarcinoma. Previous tumor tissue testing is acceptable. Please refer to the "additional HCC cohort criteria" below.
  • The subject has disease that is not amenable to curative-intent management (e.g., oligometastatic disease)
  • Measurable disease per RECIST v1.1 as determined by the investigator
  • Patients must be appropriate candidates for first-line, SOC treatment.

    • SOC treatment as defined by NCCN® guidelines or institutional standard is allowable, however, options restricted to:

      • Colorectal: FOLFOX or FOLIFIRI +/- bevacizumab
      • Pancreatic: mFOLFIRINOX
      • HCC: Tremelimumab/Durvalumab
    • Patients are eligible who received prior perioperative chemotherapy for curative intent treatment and recurred ≥ 6 months since last dose of chemotherapy.
  • ≥ 18 years old on day of consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate archival frozen or fixed tissue available from primary or metastatic site for genotypic analysis (at least 15 unstained slides and/or tumor block)
  • Adequate hematologic and organ function laboratory values as follows:

    • The ANC ≥ 1500/mm3 without colony stimulating factor support;
    • Platelets ≥ 75,000/mm3;
    • Hemoglobin ≥ 9 g/dL;
    • Bilirubin ≤ 1.5 ´ the ULN. For subjects with known Gilbert's disease, bilirubin ≤ 3.0 mg/dL;
    • Serum albumin ≥ 2.8 g/dl;
    • ALT and AST ≤ 3.0 ´ ULN;
    • Serum creatinine ≤ 1.5 ´ ULN or creatinine clearance (CrCl) ≥ 40 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used:

      • Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72);
      • Female: Multiply above result by 0.85;
  • The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document
  • Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control or practice abstinence during the study and for 4 months after the last dose of study drug(s);

Additional Inclusion Criteria for HCC Cohort ONLY:

  • Histologically or radiologically confirmed hepatocellular carcinoma (per AASLD/EASL criteria)
  • Unresectable or advanced HCC not amenable to curative surgery or locoregional therapy.
  • Barcelona Clinic Liver Cancer (BCLC) stage B or C.
  • Child-Pugh Score Class A; or Child-Pugh Class B7 or B8 at discretion of treating physician
  • Patients with HBV infection, characterized by positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV deoxyribonucleic acid (DNA) (≥10 IU/mL or above the limit of detection per local or central lab standard), must be treated with antiviral therapy, as per institutional practice to ensure adequate viral suppression (HBV DNA <2000 IU/mL) before enrolment. Patients must remain on antiviral therapy for the duration of their participation in the EAP and for 6 months after the last dose of EAP medication. Patients who test positive for anti-hepatitis B core (HBc) with undetectable HBV DNA (<10 IU/mL or under the limit of detection per local or central lab standard) do not require anti-viral therapy before enrolment. These participants will be tested at every cycle to monitor HBV DNA levels and initiate anti-viral therapy if HBV DNA is detected (≥10 IU/mL or above the limit of detection per local or central lab standard). HBV DNA detectable patients must initiate and remain on anti-viral therapy for time they are on the EAP and for 6 months after the last dose of EAP medication.

    o Note: Testing required for subjects with a known history otherwise not required.

  • Patients with HCV infection must have confirmed diagnosis of HCV characterized by the presence of detectable HCV ribonucleic acid (RNA) or anti-HCV antibody upon enrolment (management of this disease is per local institutional practice).

Exclusion Criteria

  • The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) for metastatic and/or unresectable disease.
  • BMI < 25 kg/m2
  • For colorectal cancer only - Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors.
  • For colorectal cancer only - BRAF V600E mutant tumors.
  • A personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
  • A prior hypersensitivity reaction to semaglutide or any of the excipients in WEGOVY®. Serious hypersensitivity reaction, including anaphylaxis and angioedema, have been reported with WEGOVY®.
  • Cachexia
  • Subjects on insulin.
  • Subjects with a history of diabetic retinopathy
  • Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment
  • The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    o Cardiovascular disorders including:

    • For patients being considered for bevacizumab (or bevacizumab biosimilar) only:
  • Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment;
  • thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (eg, vena cava filter) within 6 months before the first dose of study treatment.

    • Any of the following within 6 months before the first dose of study treatment:
  • unstable angina pectoris;
  • clinically-significant cardiac arrhythmias;
  • stroke (including transient ischemic attack (TIA), or other ischemic event);
  • myocardial infarction;

    • GI disorders particularly those associated with a high risk of perforation or fistula formation including:

      • Unresolved abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess.
      • Uncontrolled nausea, vomiting, or abdominal pain.
    • Other clinically significant disorders that would preclude safe study participation
  • Major surgery within 8 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
  • Females who are known or suspected to be pregnant or lactating. Women of childbearing potential must have a negative serum pregnancy test result within screening.
  • Female patients planning on becoming pregnant while on study.
  • Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment.
  • Male subjects unwilling to abstain from donating sperm during treatment.
  • Inability to comply with self-administration of GLP-1 RA subcutaneous injections.
  • Subject has known sensitivity to any of the products or components to be administered during dosing.
  • Concurrent use of other semaglutide containing products or any other GLP-1 receptor agonist.
  • Diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.
  • Subject likely to not be available to complete all protocol-required study visits or procedures and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
  • History or evidence of any other clinically significant disorder, condition or disease that in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.

Additional Exclusion Criteria for HCC Cohort ONLY:

  • Child-Pugh Score Class B9; or Child-Pugh Class C
  • Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days of the first dose of EAP treatments.
  • History of allogenic organ transplantation (e.g., liver transplant).
  • History of hepatic encephalopathy within the past 12 months or requirement for medications to prevent or control encephalopathy (e.g., no lactulose, rifaximin, etc if used for purposes of hepatic encephalopathy.
  • Clinically meaningful ascites, defined as any ascites requiring non-pharmacologic intervention (e.g., paracentesis) to maintain symptomatic control, within 2 months before the first EAP treatment dose. Patients on stable doses of diuretics for ascites for ≥2 months are eligible.
  • Patients with main portal vein thrombosis (i.e., thrombosis in the main trunk of the portal vein, with or without blood flow) on baseline imaging.
  • Active or previously documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [except for diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). Patients without active disease in the last 5 years are excluded unless discussed with the Treating Physician and considered appropriate for EAP participation. The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients with celiac disease controlled by diet alone
  • Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV). HBV positive (presence of HbsAg and/or anti-HBcAb with detectable HBV DNA); HCV positive (presence of anti-HCV antibodies); HDV positive (presence of anti-HDV antibodies).

    o Note: Testing required for subjects with a known history otherwise not required.

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
  • History of active primary immunodeficiency.
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of EAP treatment. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    • Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan pre-medication)
  • Receipt of live attenuated vaccine within 30 days before first dose of treatment. Note: patients, if enrolled, should not receive live vaccine while receiving study treatment, and up to 30 days after the last dose of study treatment.
  • Previous randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
  • Patients who have received anti-PD-1, anti-PD-L1, or anti-CTLA-4 before the first dose of EAP treatment.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Metastatic Colorectal Adenocarcinoma (CRC)
10 patients with a diagnosis of 1st line metastatic or unresectable CRC and a BMI >25 will receive GLP1 RA weekly + SOC treatment for 6 months or disease progression whichever comes first. SOC treatment for CRC is FOLFOX or FOLFIRI +/- bevacizumab.
Patients will receive 6 months of weekly semaglutide; weekly subcutaneous injection; dose escalation will occur every 4 weeks with dose titration as follows: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → Maintenance at 2.4 mg or 1.7 mg pending tolerability.
実験的:Metastatic Hepatocellular Carcinoma (HCC)
10 patients with a diagnosis of 1st line metastatic or unresectable HCC and a BMI >25 will receive GLP1 RA weekly + SOC treatment for 6 months or disease progression whichever comes first. SOC treatment for HCC is Tremelimumab/Durvalumab.
Patients will receive 6 months of weekly semaglutide; weekly subcutaneous injection; dose escalation will occur every 4 weeks with dose titration as follows: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → Maintenance at 2.4 mg or 1.7 mg pending tolerability.
実験的:Metastatic Pancreatic Adenocarcinoma (PDAC)
30 patients with a diagnosis of 1st line metastatic or unresectable PDAC, CRC, or HCC and a BMI >25 will receive GLP1 RA weekly + SOC treatment for 6 months or disease progression whichever comes first. SOC treatment for pancreatic cancer is modified FOLFIRINOX.
Patients will receive 6 months of weekly semaglutide; weekly subcutaneous injection; dose escalation will occur every 4 weeks with dose titration as follows: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → Maintenance at 2.4 mg or 1.7 mg pending tolerability.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Treatment Emergent Adverse Events [Safety] attributed to GLP1-RA and/or its interaction with chemotherapy
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Safety is defined as the incidence of grade ≥3 adverse events (AEs) as defined by CTCAE v5.0, attributed to GLP-1 RA and/or its interaction with chemotherapy
Up to 6 months or at time of disease progression, whichever comes first

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of patients who complete planned chemotherapy with concurrent GLP-1 RA without Dose Modifications or Early Termination [Tolerability]
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Endpoints for this outcome include: proportion of patients who complete planned chemotherapy with concurrent GLP-1 RA without unplanned dose reductions or delays > 14 days; dose modifications; early termination: rate of early study withdrawal or discontinuation due to treatment-related adverse effects.
Up to 6 months or at time of disease progression, whichever comes first
Overall Response Rate [Efficacy]
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Overall response rate (ORR) will be measured using the radiographic objective Response Rate as defined by RECIST v1.1
Up to 6 months or at time of disease progression, whichever comes first
Progression Free Survival [Efficacy]
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Progression free survival (PFS) is defined as the duration on treatment until progression as measured from start of treatment until disease progression or death from any cause. We will use 95% CI for PFS on those patients deemed efficacy eligible.
Up to 6 months or at time of disease progression, whichever comes first

その他の成果指標

結果測定
メジャーの説明
時間枠
Evaluate changes in serologic markers of inflammation and metabolism (Fasting glucose).
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Changes in serologic markers of inflammation and metabolism will be measured by looking at multiple labs that measure Glycemic control and Insulin resistance as well as Inflammatory and Metabolic biomarkers. Fasting glucose is a measure of blood sugar when it should be at its lowest. Changes will be presented via repeated measures, ANOVA, or mixed-effects modeling.
Up to 6 months or at time of disease progression, whichever comes first
Evaluate changes in serologic markers of inflammation and metabolism (HbA1c).
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Changes in serologic markers of inflammation and metabolism will be measured by looking at multiple labs that measure Glycemic control and Insulin resistance as well as Inflammatory and Metabolic biomarkers. HbA1c is a lab that measures average blood sugar levels over 2-3 months. Changes will be presented via repeated measures, ANOVA, or mixed-effects modeling.
Up to 6 months or at time of disease progression, whichever comes first
Evaluate changes in serologic markers of inflammation and metabolism (HOMA-IR).
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Changes in serologic markers of inflammation and metabolism will be measured by looking at multiple labs that measure Glycemic control and Insulin resistance as well as Inflammatory and Metabolic biomarkers. HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) is a mathematical score used to measure insulin resistance. Changes will be presented via repeated measures, ANOVA, or mixed-effects modeling.
Up to 6 months or at time of disease progression, whichever comes first
Evaluate changes in serologic markers of inflammation and metabolism (CRP).
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Changes in serologic markers of inflammation and metabolism will be measured by looking at multiple labs that measure Glycemic control and Insulin resistance as well as Inflammatory and Metabolic biomarkers. CRP (C-Reactive Protein) is a lab used to test for inflammation. Changes will be presented via repeated measures, ANOVA, or mixed-effects modeling.
Up to 6 months or at time of disease progression, whichever comes first
Evaluate changes in serologic markers of inflammation and metabolism (IL-6).
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Changes in serologic markers of inflammation and metabolism will be measured by looking at multiple labs that measure Glycemic control and Insulin resistance as well as Inflammatory and Metabolic biomarkers. Interleukin-6 (IL-6) is an essential protein and inflammatory cytokine that regulates the body's immune system, fever response, and inflammation. Changes will be presented via repeated measures, ANOVA, or mixed-effects modeling.
Up to 6 months or at time of disease progression, whichever comes first
Evaluate changes in serologic markers of inflammation and metabolism (Adiponectin).
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Changes in serologic markers of inflammation and metabolism will be measured by looking at multiple labs that measure Glycemic control and Insulin resistance as well as Inflammatory and Metabolic biomarkers. Adiponectin is a protein hormone produced by adipose tissue that regulates metabolism, improves insulin sensitivity, and reduces inflammation. Changes will be presented via repeated measures, ANOVA, or mixed-effects modeling.
Up to 6 months or at time of disease progression, whichever comes first
Evaluate changes in serologic markers of inflammation and metabolism (Leptin).
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Endpoints for this measure include glycemic control and insulin resistance - change in fasting glucose, HbA1c, and HOMA-IR and inflammatory and metabolic biomarkers - serial changes in CRP, IL-6, adiponectin, leptin, and insulin.
Up to 6 months or at time of disease progression, whichever comes first
Evaluate changes in serologic markers of inflammation and metabolism (Insulin).
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Changes in serologic markers of inflammation and metabolism will be measured by looking at multiple labs that measure Glycemic control and Insulin resistance as well as Inflammatory and Metabolic biomarkers. The insulin lab test measures the amount of insulin in the blood stream. Changes will be presented via repeated measures, ANOVA, or mixed-effects modeling.
Up to 6 months or at time of disease progression, whichever comes first
Evaluate changes in serologic markers of inflammation and metabolism (Glucagon).
時間枠:Up to 6 months or at time of disease progression, whichever comes first
Changes in serologic markers of inflammation and metabolism will be measured by looking at multiple labs that measure Glycemic control and Insulin resistance as well as Inflammatory and Metabolic biomarkers. The glucagon lab test measures the amount of glucagon in the blood stream. Changes will be presented via repeated measures, ANOVA, or mixed-effects modeling.
Up to 6 months or at time of disease progression, whichever comes first
Measure changes in performance status
時間枠:Up to 6 months or at time of disease progression, whichever comes first.

Performance status will be measured using the ECOG scale. ECOG is a performance status scale with grading from 0-5.

0=Normal Activity.

  1. Symptoms, but ambulatory
  2. In bed <50% of the time
  3. In bed >50% of the time 4=100% bedridden

5=Dead.

Up to 6 months or at time of disease progression, whichever comes first.
Measure changes in body weight
時間枠:Up to 6 months or at time of disease progression, whichever comes first.
Change in Body Weight: % change from baseline to 3 and 6 months.
Up to 6 months or at time of disease progression, whichever comes first.
Evaluate changes in diet
時間枠:Up to 12 months
Measuring change in diet focusing on approximate intake of fruits and vegetables, percentage energy from fat, and fiber using the Multifactor Screener. asks respondents to report how frequently they consume foods in 16 categories. Patients will be asked to complete the questionnaire at baseline, during several timepoints throughout the treatment period (6 months), at end of treatment, and follow-up. The follow-up period is 6 months after end of treatment.
Up to 12 months
Evaluate changes in quality of life
時間枠:Up to 12 months

Quality of life (QoL) will be evaluated using the EORTC QLQ-C30 questionnaire. This is a 30-item instrument designed to measure quality of life in all cancer patients. The QLQ-C30 is composed of both multi-item scales and single item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Scales are split up into 3 categories: Global health status/QoL, Functional Scales, and Symptom scales. A high score for a functional scale represents a high/ healthy level of functioning. A high score for global health status/QoL represents a high QoL. A high score for a symptom scale/ item represents a high level of symptomology/ problems.

Patients will take the questionnaire at baseline and during several timepoints throughout the treatment period (6 months), at end of treatment, and follow-up. The follow-up period is 6 months after end of treatment.

Up to 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Aaron J Scott, MD、University of Arizona

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月10日

一次修了 (推定)

2028年6月30日

研究の完了 (推定)

2028年6月30日

試験登録日

最初に提出

2026年5月18日

QC基準を満たした最初の提出物

2026年5月29日

最初の投稿 (実際)

2026年6月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月18日

QC基準を満たした最後の更新が送信されました

2026年9月16日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する